Literature DB >> 31707523

A rare case of pediatric moyamoya disease with reversible white matter lesions in a 3-year-old Chinese girl.

Shi-Jun Li1, Jie Xiong1, Yu He2, Yang-Yang Xiao1, Ding-An Mao1, Li-Qun Liu3.   

Abstract

Moyamoya disease is a chronic cerebral vascular disease characterized by progressive occlusion of the cerebral arteries and resulting in the development of abnormal collateral circulation. We report a case of moyamoya disease in a 3-year-old Chinese girl with partly reversible white matter lesions. This case indicates that, in pediatric moyamoya disease, white matter lesions may be associated with cerebral ischemia, and they may be reversible after treatment.

Entities:  

Keywords:  Collateral circulation; Intermittent mental abnormality; Moyamoya disease; White matter lesion

Mesh：

Year:  2019        PMID： 31707523     DOI： 10.1007/s00381-019-04391-x

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN： 0256-7040            Impact factor:   1.475


  27 in total

1.  RNF213 p.R4810K Variant and Intracranial Arterial Stenosis or Occlusion in Relatives of Patients with Moyamoya Disease.

Authors:  Yoshiko Matsuda; Yohei Mineharu; Mitsuru Kimura; Yasushi Takagi; Hatasu Kobayashi; Toshiaki Hitomi; Kouji H Harada; Yoshito Uchihashi; Takeshi Funaki; Susumu Miyamoto; Akio Koizumi
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-05-11       Impact factor: 2.136

2.  Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis).

Authors: 
Journal:  Neurol Med Chir (Tokyo)       Date:  2012       Impact factor: 1.742

3.  Clinical implications of the cortical hyperintensity belt sign in fluid-attenuated inversion recovery images after bypass surgery for moyamoya disease.

Authors:  Eika Hamano; Hiroharu Kataoka; Naomi Morita; Daisuke Maruyama; Tetsu Satow; Koji Iihara; Jun C Takahashi
Journal:  J Neurosurg       Date:  2016-02-19       Impact factor: 5.115

4.  Posterior Reversible Encephalopathy Syndrome: A Rare Childhood Case with Unconsciousness.

Authors:  Akira Komori; Daisuke Mizu; Koichi Ariyoshi
Journal:  J Emerg Med       Date:  2018-01-12       Impact factor: 1.484

5.  Moyamoya disease in a child with previous acute necrotizing encephalopathy.

Authors:  Taik-Kun Kim; Baik-Lin Eun; Sang Hoon Cha; Kyoo Byung Chung; Jung Hyuck Kim; Baek Hyun Kim; Hwan Hoon Chung
Journal:  Pediatr Radiol       Date:  2003-06-12

6.  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.

Authors:  Wanyang Liu; Daisuke Morito; Seiji Takashima; Yohei Mineharu; Hatasu Kobayashi; Toshiaki Hitomi; Hirokuni Hashikata; Norio Matsuura; Satoru Yamazaki; Atsushi Toyoda; Ken-ichiro Kikuta; Yasushi Takagi; Kouji H Harada; Asao Fujiyama; Roman Herzig; Boris Krischek; Liping Zou; Jeong Eun Kim; Masafumi Kitakaze; Susumu Miyamoto; Kazuhiro Nagata; Nobuo Hashimoto; Akio Koizumi
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

Review 7.  Research Progress of Moyamoya Disease in Children.

Authors:  Jianmin Piao; Wei Wu; Zhongxi Yang; Jinlu Yu
Journal:  Int J Med Sci       Date:  2015-07-03       Impact factor: 3.738

Review 8.  Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review.

Authors:  Xin Liao; Jing Deng; Wenjie Dai; Tong Zhang; Junxia Yan
Journal:  Environ Health Prev Med       Date:  2017-11-02       Impact factor: 3.674

9.  Rare Presentation of Moyamoya Disease with Sub acute Presentation in Iran.

Authors:  Payam Sasannejad; Fateme Rezaei; Reza Bidaki; Ehsan Zarepur
Journal:  Iran J Child Neurol       Date:  2018

10.  Dysregulation of RNF213 promotes cerebral hypoperfusion.

Authors:  Takaaki Morimoto; Jun-Ichiro Enmi; Yorito Hattori; Satoshi Iguchi; Satoshi Saito; Kouji H Harada; Hiroko Okuda; Yohei Mineharu; Yasushi Takagi; Shohab Youssefian; Hidehiro Iida; Susumu Miyamoto; Masafumi Ihara; Hatasu Kobayashi; Akio Koizumi
Journal:  Sci Rep       Date:  2018-02-26       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.